Returns From Sanofi Consumer Expansion Could Point To More
This article was originally published in The Pink Sheet
The French pharma's strategy of driving consumer health business growth by expanding the product lineup played out during the first quarter with the launch of OTC switch Xyzal Allergy and with further integration of OTC drug and vitamin brands recently acquired from Boehringer Ingelheim.
You may also be interested in...
Sanofi consumer health chief Alan Main says with the US the largest OTC drug market, a successful switch for Tamiflu, marketed in the US by Roche subsidiary Genentech, would support the firm's global strategy for expanding cough and cold remedy sales.
Sanofi wants to keep all its current businesses under the same roof, including consumer health, says CEO Olivier Brandicourt. "We think we have now the right structure," Brandicourt responds to question on whether Sanofi would follow other large pharmas in positioning consumer health or other divisions for separation.
Sanofi consumer products head Alan Main says BI's brands will "lift Sanofi into leadership positions in attractive OTC categories, namely the vitamins and minerals supplements market, digestive products, cough and cold as well as pain medications."